Recent advances in molecular and genetic research into ependymomas have identified potential therapeutic targets that could pave the way for more targeted treatments in the future.1 These include agents that inhibit specific proteins or signaling pathways, such as topoisomerase inhibitors or inhibitors of HIF-1α and STAT3. Here, HIF1A is linked to ependymoma.